The participating companies—AnnJi Pharmaceutical, Leadgene Biosolutions, FEBICO, PharmiGENE, TAHO Pharma, and Instant NanoBiosensors—represent a diverse cross-section of Taiwan’s evolving biotech landscape. Their offerings span from rare disease drug development and pharmacogenomics to bioprocessing instrumentation and microalgae-based therapeutics. This delegation arrives as the global industry seeks to shorten development timelines and improve manufacturing scalability, areas where these firms are positioning their proprietary technologies for international licensing and co-development.
In section Releases
Taiwanese Biotech Firms Target Global Partnerships at BIO 2026
The Taipei City Government is dispatching a delegation of six biotechnology firms to the BIO 2026 International Convention in San Diego, aiming to pivot from domestic focus to global commercialization. The group highlights a shift in Taiwan’s life sciences sector toward late-stage clinical assets and advanced diagnostic platforms.
AnnJi Pharmaceutical is notably presenting AJ201, an androgen receptor degrader currently ready for Phase 3 trials targeting Kennedy’s Disease. Meanwhile, firms like Leadgene Biosolutions and Instant NanoBiosensors are addressing infrastructure bottlenecks in cell line development and precision diagnostics. By showcasing these capabilities in San Diego, the delegation aims to secure the strategic partnerships necessary to translate regional scientific success into global clinical impact.
Comments (0)
No comments yet. Be the first!